CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 6.5% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics (NASDAQ: CRSP) is a biotech company specializing in gene-editing technology. The company has been gaining attention for its innovative treatments for genetic disorders.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 6.5% on Jun 5, 2026 14:06

• Despite recent positive developments like shareholder approvals, increased price targets, and high call options volume, CRSP recently experienced a bearish trend.
• Analysts suggest that the stock's decline may be due to profit-taking following a substantial price increase, with investors capitalizing on gains by selling shares.
• Additionally, the slight decrease in stock value since the last earnings update could also be a factor in this downward movement, with investor sentiment possibly influenced by concerns about the company's financial position.
• In a broader perspective, this market shift might represent a temporary correction linked to the prior bullish momentum, possibly offering an attractive buying opportunity for investors who believe in the long-term potential of CRISPR Therapeutics.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

CRISPR Therapeutics (NASDAQ: CRSP) investors approve 2026 plan and capital changes

CRISPR Therapeutics shareholders approved all management proposals at their annual meeting on June 4, 2026. Key approvals included the adoption of a new 2026 Stock Option and Incentive Plan, amendments to the company’s Swiss articles of association to increase the capital band and conditional share capital, and the re-election of all eleven directors and compensation committee members. Shareholders also approved the 2025 financial statements and executive compensation votes.

https://www.stocktitan.net/sec-filings/CRSP/8-k-crispr-therapeutics-ag-reports-material-event-f867fd10ed10.html

CRSP Stock Climbs As Wall Street Lifts Price Targets

CRISPR Therapeutics AG (CRSP) stock climbed over 10.68% after multiple Wall Street firms, including Citi, Evercore ISI, and Bank of America, updated their price targets and reiterated positive ratings. Despite reporting a Q1 2026 loss, the company's strong cash position and gene-editing pipeline are attracting investor interest, prompting aggressive dip buying and demonstrating momentum-driven trading. Analysts point to a supportive biotech environment for gene-editing companies as a key driver for the stock's current performance.

https://stockstotrade.com/news/crispr-therapeutics-ag-crsp-news-2026_06_04/

Stock Traders Buy High Volume of CRISPR Therapeutics Call Options (NASDAQ:CRSP)

Stock traders recently showed unusual options activity for CRISPR Therapeutics (NASDAQ:CRSP), buying 6,090 call options, a 66% increase over the average daily volume. This surge happened despite recent insider selling by the CEO and General Counsel, totaling $2.31 million in the last 90 days. The stock rose 12.5% to $58.62, and analysts maintain a "Moderate Buy" consensus with an average target price of $65.47.

https://www.marketbeat.com/instant-alerts/stock-traders-buy-high-volume-of-crispr-therapeutics-call-options-nasdaqcrsp-2026-06-04/

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

CRISPR Therapeutics (CRSP) stock shows significant upside potential, with Wall Street analysts projecting up to 437% growth. This optimism stems from the recent commercialization of its gene-editing treatment, Casgevy, which effectively treats sickle cell disease and beta thalassemia, and the company's robust drug pipeline. Despite currently trading at a high multiple of next year's revenue, the long-term prospects, driven by revolutionary gene-editing technology and a vast patient pool, suggest the stock is undervalued for investors willing to take a speculative position.

https://www.fool.com/investing/2026/06/03/crispr-therapeutics-stock-cheap-upside-crsp/

Why is CRISPR Therapeutics (CRSP) down 0.7% since last earnings report?

This article analyzes why CRISPR Therapeutics (CRSP) stock has declined by 0.7% since its last earnings report. It suggests further research is needed to understand the specific factors contributing to this dip.

https://www.msn.com/en-us/money/companies/why-is-crispr-therapeutics-crsp-down-0-7-since-last-earnings-report/ar-AA24KRJP

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.2% Today

XRP ($XRP) Crypto Forecast: Up 5.8% Today

ZCash ($ZEC) Crypto Forecast: Up 17.4% Today

CRISPR Therapeutics AG Price History

08.04.2026 - CRSP Stock was up 5.2%

• Despite a wider loss than anticipated and revenue results falling short in the initial quarter, CRISPR Therapeutics AG (CRSP) shares rose by 3.8% during midday trading, indicating positive market sentiment.
• Investor interest seems to be more focused on the company's advancements in product approvals, pipeline expansion, and strategic collaborations rather than solely on financial performance.
• The stock's upward movement may also be influenced by analysts upholding a "Moderate Buy" rating for CRSP shares, with an average price target of $64.53, underscoring faith in the company's long-term growth trajectory.
• The conflicting financial results suggest that while revenue challenges exist, the market holds an optimistic view on CRISPR Therapeutics AG's future prospects in the gene therapy sector.

02.05.2026 - CRSP Stock was down 5.2%

• The bearish movement in CRSP stock today could be attributed to the Chief Medical Officer's mandated RSU tax sale, which might have led to some uncertainty among investors.
• Additionally, the significant reduction in stake by Koss Olinger Consulting LLC could have also contributed to the downward pressure on the stock price.
• Despite these short-term factors, the company's participation in upcoming investor conferences and its strong position in gene-based medicines suggest long-term growth potential, which investors should consider amidst the current market volatility.

27.04.2026 - CRSP Stock was up 5.5%

• The positive movement in CRSP stock today is due to the company reporting encouraging Q1 2026 results, including improved financials with a reduced net loss and a significant increase in cash position. Revenue from CASGEVY and the optimistic outlook shared by CEO Samarth Kulkarni have likely bolstered investor confidence.
• Investor interest in CRSP has been reignited by positive earnings revisions and advancements in the CASGEVY rollout, leading to enhanced long-term growth prospects and a favorable valuation compared to industry peers. This renewed interest may have further contributed to the positive movement in the stock.
• Despite encountering competitive pressures and financial setbacks, the expanding pipeline of CRISPR Therapeutics with promising clinical outcomes and potential revenue growth from label extensions may also have influenced the surge in the stock price today. Investors appear to be focusing on the company's future potential rather than its current challenges.

22.04.2026 - CRSP Stock was up 5.0%

• CRISPR Therapeutics (CRSP) observed a significant upturn in the market today.
• This surge in market performance is linked to the recent announcement of reduced losses in the first quarter of 2026 and the favorable advancements made with Casgevy.
• Investor interest has piqued in CRSP due to its efforts to enhance the capabilities of Casgevy and the upcoming data releases for new programs across various therapeutic domains.
• Analysts have provided a range of fair value estimates for CRSP, and the optimistic outlook surrounding the company's progress is likely driving the positive market momentum experienced by the stock.

05.05.2026 - CRSP Stock was down 6.5%

• Despite recent positive developments like shareholder approvals, increased price targets, and high call options volume, CRSP recently experienced a bearish trend.
• Analysts suggest that the stock's decline may be due to profit-taking following a substantial price increase, with investors capitalizing on gains by selling shares.
• Additionally, the slight decrease in stock value since the last earnings update could also be a factor in this downward movement, with investor sentiment possibly influenced by concerns about the company's financial position.
• In a broader perspective, this market shift might represent a temporary correction linked to the prior bullish momentum, possibly offering an attractive buying opportunity for investors who believe in the long-term potential of CRISPR Therapeutics.

15.04.2026 - CRSP Stock was down 5.2%

• The bearish movement in CRSP stock today could be attributed to profit-taking by a major investment firm, which recently reduced its stake in the company by 4.1%.
• Despite an increase in the price target for CRSP and positive forecasts from top Wall Street analysts, the stock might have experienced a bearish trend due to investors reacting to another investor disclosing a 5.1% stake in the company, potentially leading to concerns about market dilution.
• The overall market sentiment towards CRSP remains positive, with analysts maintaining a "Moderate Buy" consensus rating and highlighting the company's robust pipeline and innovative gene-editing platform as drivers for long-term growth.
• The bearish movement today could also be influenced by company insiders being net sellers in the last 90 days, adding to the selling pressure on the stock despite positive analyst outlooks.

28.04.2026 - CRSP Stock was up 5.1%

• The stock had a strong bullish movement today as the average 12-month price target was raised to $80.62, implying a 51% upside, indicating positive sentiment from analysts.
• Despite facing competitive pressures in the gene therapy market, CRISPR Therapeutics is balancing commercial progress with a strong balance sheet, positive analyst sentiment, and potential revenue growth from its expanding pipeline.
• The company's Q1 2026 results showed improved financials with a net loss reduction and increased cash position, reflecting strong execution and revenue generation from its therapy CASGEVY.
• Technical analyses and trading ideas for CRSP vary from bullish predictions based on chart patterns to cautious outlooks, but overall, the stock seems to have garnered investor interest and positive momentum.

14.04.2026 - CRSP Stock was down 5.0%

• The bearish movement in CRISPR Therapeutics' stock today can be attributed to a wider-than-expected loss in Q1 2026, coupled with sales missing analyst estimates. This disappointing financial performance likely led to a decrease in investor confidence.
• Despite a top Wall Street analyst's bullish outlook and a raised price target by Bernstein, the concerns surrounding the company's financial results may have overshadowed the positive sentiments.
• The recent reduction in stock position by Vanguard Group Inc. and the dilution concerns raised by the company's new capital raise through convertible notes could have added selling pressure on the stock.
• While CRISPR Therapeutics' innovative gene-editing platform and promising pipeline offer long-term growth potential, the current challenges in financial performance and investor uncertainty regarding its future may have driven the bearish market movement today.

06.04.2026 - CRSP Stock was up 5.8%

• CRSP stock demonstrated a 3.8% increase in midday trading, suggesting that investors could be focusing on favorable aspects of the company's performance despite the reported loss and revenue shortfall.
• The company's advancements in product approvals, pipeline development, and strategic partnerships highlighted in the financial update might have boosted investor confidence, leading to the positive market movement.
• The financial results, including a narrower loss per share than expected and revenue below projections, potentially instilled optimism that the company is effectively managing expenses and progressing strategically amid revenue challenges.
• Although insider stock sales and convertible notes offerings were noted, the overall market sentiment appears to have been influenced by the positive outlook presented in the company's financial update and future growth opportunities.

05.04.2026 - CRSP Stock was down 5.1%

• CRSP stock experienced a bearish movement today despite reporting its first-quarter 2026 financial results.
• The earnings miss, with an adjusted EPS of -$1.28 and revenue of $1.46 million falling short of expectations, likely contributed to the negative market reaction.
• Despite ongoing progress in product approvals and pipeline development, the significant revenue miss compared to estimates may have raised concerns among investors about the company's financial performance.
• The discrepancy between the reported financials and the estimated fair value of the stock, indicating a potential undervaluation, could also be a factor in the bearish market movement as investors reassess the company's growth prospects and risks.

12.04.2026 - CRSP Stock was down 5.8%

• An optimistic outlook from a top Wall Street analyst suggesting a potential doubling of CRISPR Therapeutics' stock price is contrasted by a wider-than-expected loss in Q1 2026 and missed sales estimates, influencing a bearish market response.
• Despite the positive commercial uptake of CASGEVY and advancements in the gene editing pipeline, concerns about dilution from a recent capital raise and uncertainty about the company's future potential have likely contributed to the stock's decline.
• The decrease in Nwam LLC's holdings, despite positive analyst ratings, reflects a cautious stance towards CRISPR Therapeutics, particularly given its high-risk pre-profitability stage and recent quarterly losses.
• Data on the number of shareholders, while not indicative of market sentiment, underscores the ongoing interest and activity surrounding CRISPR Therapeutics' stock.

04.05.2026 - CRSP Stock was up 11.9%

• Analysts are optimistic about CRISPR Therapeutics (CRSP) stock, with projections indicating a potential growth of up to 437%, likely fueling the upward momentum.
• The launch of Casgevy, its gene-editing treatment for sickle cell disease and beta thalassemia, along with a strong drug pipeline, is driving positive sentiment among investors.
• The recent allocation of restricted stock units (RSUs) as equity awards to the CFO and Chief Medical Officer is seen as a measure to align their interests with company performance, potentially increasing investor confidence in future prospects.
• While there was a minor decrease post the last earnings update, the overall outlook for CRISPR Therapeutics (CRSP) appears promising, leading investors to gravitate towards growth opportunities in the biotech industry.